contusugene ladenovec
AXP000142.1 · Viral vector gene therapy
- Platform
- adenovirus (Ad5, E1-deleted, CMV promoter-driven TP53)
- Targets
- TP53
- Originator
- Introgen Therapeutics
- Sponsor
- Introgen Therapeutics
Names
| Name | Type | Source |
|---|---|---|
| contusugene ladenovec | preferred name, INN | curator, ncit |
| Advexin | brand | ncit |
| INGN 201 | code | ncit |
| Ad-p53 ambiguous | synonym | ncit |
| Ad5CMV p53 Gene ambiguous | synonym | ncit |
| RPR/INGN-201 | former code | ncit |
Virus
- Role
- In vivo gene transfer
- Family
- Adenoviridae
- Virus
- human adenovirus 5 (NCBI Taxonomy 28285)
- Strain
- Ad5
- Replication
- non replicating
- Modifications
- E1-deleted (replication-defective); CMV promoter-driven wild-type TP53
- Transgenes
- TP53
- Route
- intratumoral
- Source
- evidence
Cross-references
- NCI Thesaurus
- C2471
- FDA UNII
- YPN57899MY
Approvals
No regulatory approval recorded.
Clinical trials (9)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT01302821 | C11 AMT Positron Emission Tomography (PET) Imaging in Patients With Metastatic Invasive Breast Cancer | Withdrawn | 2013-01 | 2014-12 | 0 | Breast Cancer | |
| NCT00410865 | Wild Type p53 Adenovirus for Oral Premalignancies | Terminated | Phase 1 | 2003-06 | 2008-03 | 4 | Mouth Cancer |
| NCT00064103 | Gene Therapy in Preventing Cancer in Patients With Premalignant Carcinoma of the Oral Cavity or Pharynx | Completed | Phase 1/2 | 2003-06 | 2007-08 | 51 | Lip and Oral Cavity Cancer; Oropharyngeal Cancer; Stage 0 Lip and Oral Cavity Cancer; Stage 0 Oropharyngeal Cancer; Tongue Cancer |
| NCT00017173 | S0011, Gene Therapy & Surgery Followed by Chemo & RT in Newly Diagnosed Cancer of the Mouth or Throat | Terminated | Phase 2 | 2003-02 | 2007-05 | 13 | Head and Neck Cancer |
| NCT00044993 | Chemotherapy Combined With Gene Therapy in Treating Patients Who Have Stage III or Stage IV Breast Cancer | Completed | Phase 2 | 2002-02 | Breast Cancer | ||
| NCT00003167 | Gene Therapy in Treating Patients With Advanced Bladder Cancer | Completed | Phase 1 | 1998-05 | 2002-12 | 24 | Recurrent Bladder Cancer; Stage I Bladder Cancer; Stage II Bladder Cancer; Stage III Bladder Cancer; Stage IV Bladder Cancer; Transitional Cell Carcinoma of the Bladder |
| NCT00286247 | Study to Determine the Efficacy and Safety of Docetaxel and Doxorubicin With INGN 201 in Locally Advanced Breast Cancer | Completed | Phase 2 | 60 | Locally Advanced Breast Cancer (LABC) | ||
| NCT00041626 | Effectiveness and Safety of INGN 201 in Combination With Chemotherapy Versus Chemotherapy Alone | Unknown | Phase 3 | Carcinoma, Squamous Cell | |||
| NCT00041613 | Study to Compare the Overall Survival of Patients Receiving INGN 201 (Study Drug) With Patients Receiving Methotrexate | Unknown | Phase 3 | Carcinoma, Squamous Cell |
Unconfirmed matches (12)
Trials that mention one of the names in a weaker way (a code only in the title, a short or ambiguous name). Not counted above.
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions | Matched by |
|---|---|---|---|---|---|---|---|---|
| NCT07150416 | Nebulized Inhalation of Recombinant Human p53 Adenovirus Injection for Treatment of Multiple Ground-Glass Lung Nodules: A Single-Arm Clinical Study | Not yet recruiting | Phase 2 | 2025-10-01 | 2026-12-01 | 38 | Lung Neoplasms; Multiple Pulmonary Ground-Glass Nodules; Precancerous Conditions | name in intervention: Ad-p53 |
| NCT02842125 | Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer | Terminated | Phase 1/2 | 2018-11-20 | 2020-05-08 | 4 | Metastatic Solid Tumor Cancer; Recurrent Head and Neck Cancer | intervention named: Ad-p53 |
| NCT03544723 | Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors. | Unknown | Phase 2 | 2018-10-01 | 2022-06-30 | 40 | Lymphoma; Solid Tumor | intervention named: Ad-p53 |
| NCT01042535 | Vaccine Therapy and 1-MT in Treating Patients With Metastatic Breast Cancer | Completed | Phase 1/2 | 2009-12-28 | 2014-12-01 | 44 | Male Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer; Unspecified Adult Solid Tumor, Protocol Specific | name in intervention: Ad-p53 |
| NCT00004225 | Gene Therapy Plus Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer | Completed | Phase 1 | 2000-01 | Lung Cancer | intervention named: Ad5CMV p53 Gene | ||
| NCT00004041 | Gene Therapy in Treating Patients With Recurrent Malignant Gliomas | Completed | Phase 1 | 1999-02-25 | 2002-07-22 | Brain and Central Nervous System Tumors | intervention named: Ad5CMV p53 Gene | |
| NCT00004038 | Gene Therapy Plus Chemotherapy in Treating Patients With Breast Cancer | Completed | Phase 1 | 1999-01 | 2001-05 | 20 | Breast Cancer | intervention named: Ad5CMV p53 Gene |
| NCT00003649 | Gene Therapy in Treating Patients With Non-small Cell Lung Cancer That Cannot Be Surgically Removed | Completed | Phase 1 | 1998-11-17 | Lung Cancer | intervention named: Ad5CMV p53 Gene | ||
| NCT00003588 | Gene Therapy in Treating Patients With Ovarian Cancer | Completed | Phase 1 | 1998-09 | 2002-03 | 30 | Ovarian Cancer | intervention named: Ad5CMV p53 Gene |
| NCT00003450 | Gene Therapy in Treating Patients With Advanced Recurrent or Persistent Ovarian Cancer or Primary Peritoneal Cancer | Completed | Phase 1 | 1998-09 | 1999-01 | Ovarian Cancer; Peritoneal Cavity Cancer | intervention named: Ad5CMV p53 Gene | |
| NCT00003147 | Gene Therapy in Treating Patients With Cancer of The Liver | Terminated | Phase 1 | 1998-02 | 2003-06 | 30 | Liver Cancer | intervention named: Ad5CMV p53 Gene |
| NCT00003257 | Gene Therapy in Treating Patients With Recurrent Head and Neck Cancer | Unknown | Phase 2 | 1998-01 | 39 | Head and Neck Cancer | intervention named: Ad5CMV p53 Gene |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 19770418 | A phase 2 trial of surgery with perioperative INGN 201 (Ad5CMV-p53) gene therapy followed by chemoradiotherapy for advanced, resectable squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and larynx: report of the Southwest Oncology Group. | Archives of otolaryngology--head & neck surgery | 2009 | cited by trial NCT00017173 |
| PMID 19086841 | Potential of Advexin: a p53 gene-replacement therapy in Li-Fraumeni syndrome. | Future oncology (London, England) | 2008 | name in title: Advexin |
| PMID 17483435 | p53 therapy in a patient with Li-Fraumeni syndrome. | Molecular cancer therapeutics | 2007 | name in abstract: Advexin |
| PMID 16648505 | Phase I, pharmacokinetic, and pharmacodynamic study of intravenously administered Ad5CMV-p53, an adenoviral vector containing the wild-type p53 gene, in patients with advanced cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2006 | name in abstract: INGN 201 |
| PMID 16734736 | Phase I/II adenoviral p53 gene therapy for chemoradiation resistant advanced esophageal squamous cell carcinoma. | Cancer science | 2006 | name in abstract: INGN 201 |
| PMID 15297186 | A phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum- and paclitaxel-resistant epithelial ovarian cancer. | Gynecologic oncology | 2004 | name in title: INGN 201 |
| PMID 15553716 | [A case of advanced non-small lung cancer responding to tumor suppressor p53 gene therapy]. | Gan to kagaku ryoho. Cancer & chemotherapy | 2004 | name in abstract: Advexin |
| PMID 12538456 | Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2003 | name in title: INGN 201 |
| PMID 12805322 | Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2003 | name in abstract: INGN 201 |
| PMID 12839017 | Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2003 | name in abstract: INGN 201 |
| PMID 14599679 | Development and validation of a real-time PCR assay for the detection and quantitation of p53 recombinant adenovirus in clinical samples from patients treated with Ad5CMV-p53 (INGN 201). | Journal of virological methods | 2003 | name in title: INGN 201 |
Unconfirmed matches (3)
Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 30591959 | Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancer. | Cancer immunology, immunotherapy : CII | 2019 | name in title: Ad-p53 |
| PMID 19958629 | [Clinical research on recombinant human Ad-p53 injection combined with cisplatin in treatment of malignant pleural effusion induced by lung cancer]. | Ai zheng = Aizheng = Chinese journal of cancer | 2009 | name in title: Ad-p53 |
| PMID 10811470 | Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type. P53 (Ad-p53). | Cancer gene therapy | 2000 | name in title: Ad-p53 |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 35756634 | Role of Adenoviruses in Cancer Therapy. | Frontiers in oncology | 2022 | name in abstract: Advexin |
| PMID 31933185 | Current Prospects of Molecular Therapeutics in Head and Neck Squamous Cell Carcinoma. | Pharmaceutical medicine | 2019 | name in abstract: Advexin |
| PMID 26052534 | Re-examination of regulatory opinions in Europe: possible contribution for the approval of the first gene therapy product Glybera. | Molecular therapy. Methods & clinical development | 2015 | name in abstract: contusugene ladenovec |
| PMID 25364261 | Clinical utility of recombinant adenoviral human p53 gene therapy: current perspectives. | OncoTargets and therapy | 2014 | name in abstract: Advexin |
| PMID 24107178 | Advances in adenovirus-mediated p53 cancer gene therapy. | Expert opinion on biological therapy | 2013 | name in abstract: Advexin |
| PMID 20222046 | Head and neck cancer: response to p53-based therapeutics. | Head & neck | 2011 | name in abstract: Advexin |
| PMID 20501801 | Preclinical evaluation of differentially targeting dual virotherapy for human solid cancer. | Molecular cancer therapeutics | 2010 | name in abstract: Advexin |
| PMID 19169960 | A review of contusugene ladenovec (Advexin) p53 therapy. | Current opinion in molecular therapeutics | 2009 | name in title: contusugene ladenovec |
| PMID 20021420 | Gene therapy: the first approved gene-based medicines, molecular mechanisms and clinical indications. | Current molecular pharmacology | 2008 | name in abstract: Advexin |
| PMID 17472413 | INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201. | Drugs in R&D | 2007 | name in title: RPR/INGN-201 |
| PMID 16856803 | INGN 201 (Advexin): adenoviral p53 gene therapy for cancer. | Expert opinion on biological therapy | 2006 | name in title: INGN 201 |
| PMID 15102659 | Evidence that transfer of functional p53 protein results in increased apoptosis in prostate cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2004 | name in abstract: INGN 201 |
| PMID 12749760 | INGN 201: Ad-p53, Ad5CMV-p53, Adenoviral p53, INGN 101, p53 gene therapy--Introgen, RPR/INGN 201. | BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy | 2003 | name in title: RPR/INGN-201 |
| PMID 14617796 | Adenovirus-mediated wild-type p53 radiosensitizes human tumor cells by suppressing DNA repair capacity. | Molecular cancer therapeutics | 2003 | name in abstract: INGN 201 |
| PMID 11339893 | Tumor suppression and therapy sensitization of localized and metastatic breast cancer by adenovirus p53. | Human gene therapy | 2001 | name in abstract: RPR/INGN-201 |
| PMID 11706402 | Clinical evaluation of adenoviral-mediated p53 gene transfer: review of INGN 201 studies. | Seminars in oncology | 2001 | name in title: INGN 201 |
| PMID 11892946 | INGN-201. Introgen Therapeutics. | Current opinion in investigational drugs (London, England : 2000) | 2001 | name in title: INGN 201 |
| PMID 11121656 | Adenoviral-mediated p53 transgene expression sensitizes both wild-type and null p53 prostate cancer cells in vitro to radiation. | International journal of radiation oncology, biology, physics | 2000 | name in abstract: RPR/INGN-201 |
| PMID 11122810 | Local delivery for gene therapy. | Current oncology reports | 1999 | name in abstract: RPR/INGN-201 |
Unconfirmed matches (22)
Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 29338444 | The First Approved Gene Therapy Product for Cancer Ad-p53 (Gendicine): 12 Years in the Clinic. | Human gene therapy | 2018 | name in title: Ad-p53 |
| PMID 25501339 | Ad-p53 enhances the sensitivity of triple-negative breast cancer MDA-MB-468 cells to the EGFR inhibitor gefitinib. | Oncology reports | 2015 | name in title: Ad-p53 |
| PMID 25876901 | [Effects of Ad-p53 plus fulvestrant on induced apoptosis in MCF-7 breast cancer cells]. | Zhonghua yi xue za zhi | 2015 | name in title: Ad-p53 |
| PMID 25623760 | [Effect of recombinant human p53 adenovirus (Ad-p53) combined with EGFR inhibitor gefitinib on the sensitivity of breast cancer MDA-MB-468 cells]. | Zhonghua zhong liu za zhi [Chinese journal of oncology] | 2014 | name in title: Ad-p53 |
| PMID 20015717 | Intratumoral delivery of docetaxel enhances antitumor activity of Ad-p53 in murine head and neck cancer xenograft model. | American journal of otolaryngology | 2010 | name in title: Ad-p53 |
| PMID 20420527 | INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect. | Expert opinion on biological therapy | 2010 | name in title: Ad-p53 |
| PMID 18443131 | Phosphorylation of Thr18 and Ser20 of p53 in Ad-p53-induced apoptosis. | Neuro-oncology | 2008 | name in title: Ad-p53 |
| PMID 18790766 | AAV-HGFK1 and Ad-p53 cocktail therapy prolongs survival of mice with colon cancer. | Molecular cancer therapeutics | 2008 | name in title: Ad-p53 |
| PMID 16886630 | Ad-fRNK and Ad-p53 cooperate to augment drug-induced death of a transformed cell line. | Anticancer research | 2006 | name in title: Ad-p53 |
| PMID 16149900 | Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. | Human gene therapy | 2005 | name in title: Ad-p53 |
| PMID 14719118 | Differential activation of the Fas/CD95 pathway by Ad-p53 in human gliomas. | International journal of oncology | 2004 | name in title: Ad-p53 |
| PMID 15510008 | Enhancement of Ad-p53 therapy with docetaxel in head and neck cancer. | The Laryngoscope | 2004 | name in title: Ad-p53 |
| PMID 12521996 | Potentiation of dexamethasone-, paclitaxel-, and Ad-p53-induced apoptosis by Bcl-2 antisense oligodeoxynucleotides in drug-resistant multiple myeloma cells. | Blood | 2003 | name in title: Ad-p53 |
| PMID 14682374 | Clinical trials of adenoviruses in brain tumors: a review of Ad-p53 and oncolytic adenoviruses. | Journal of neuro-oncology | 2003 | name in title: Ad-p53 |
| PMID 12082456 | Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500. | Cancer gene therapy | 2002 | name in title: Ad-p53 |
| PMID 12487055 | Clinical update of Ad-p53 gene therapy for lung cancer. | Surgical oncology clinics of North America | 2002 | name in title: Ad-p53 |
| PMID 11296482 | Introduction of mutant p53 into a wild-type p53-expressing glioma cell line confers sensitivity to Ad-p53-induced apoptosis. | Neuro-oncology | 2001 | name in title: Ad-p53 |
| PMID 10733544 | Detection of adenovirus and initiation of apoptosis in hepatocellular carcinoma cells after Ad-p53 treatment. | Hepatology (Baltimore, Md.) | 2000 | name in title: Ad-p53 |
| PMID 10854146 | Ad5CMVp53 gene therapy for locally advanced prostate cancer--where do we stand? | World journal of urology | 2000 | name in title: Ad5CMV p53 Gene |
| PMID 11798837 | [Experimental study on combination of Ad-p53 with CDDP or As(2)O(3) in human lung adenocarcinoma cell line GLC-82]. | Zhonghua yi xue za zhi | 2000 | name in title: Ad-p53 |
| PMID 10516606 | Bivariate analysis of the p53 pathway to evaluate Ad-p53 gene therapy efficacy. | Cytometry | 1999 | name in title: Ad-p53 |
| PMID 12496806 | Intraprostatic AD-p53 gene therapy followed by radical prostatectomy: feasibility and preliminary results. | Prostate cancer and prostatic diseases | 1999 | name in title: Ad-p53 |
NIH grants
No confirmed grants yet.
Unconfirmed matches (1)
Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.
| Project | Title | Organisation | PI | Years | Linked by |
|---|---|---|---|---|---|
| R21DE014878 | Enhancement of Ad-p53 Therapy with Intratumoral Taxane | WAYNE STATE UNIVERSITY | YOO, GEORGE H | 2003–2004 | name in title: Ad-p53 |
Notes
Advexin; reached phase 3 in head and neck squamous cell carcinoma. FDA told Introgen in 2008 that the BLA was not sufficiently complete to file; the company restructured and the programme stopped. Ad5CMV-p53 is the construct name.
How to cite
contusugene ladenovec (AXP000142.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000142.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.